Ganciclovir - Generic Drug Details

What are the generic drug sources for ganciclovir and what is the scope of patent protection?

Ganciclovir is the generic ingredient in six branded drugs marketed by Roche Palo, Ranbaxy Labs Ltd, Bausch And Lomb, Exela Pharma, Cheplapharm, Am Regent, Custopharm Inc, Fresenius Kabi Usa, Hikma, Onesource Specialty, Ph Health, Pharmascience Inc, and Slate Run Pharma, and is included in fourteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for ganciclovir. One supplier is listed for this compound.

Summary for ganciclovir

US Patents:	1
Tradenames:	6
Applicants:	13
NDAs:	14
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	164
Drug Prices:	Drug price trends for ganciclovir
What excipients (inactive ingredients) are in ganciclovir?	ganciclovir excipients list
DailyMed Link:	ganciclovir at DailyMed

See drug prices for ganciclovir

Recent Clinical Trials for ganciclovir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	PHASE4
Peking University People's Hospital	PHASE2
Qianfo Mountain Hospital, Shandong Province	PHASE4

See all ganciclovir clinical trials

Pharmacology for ganciclovir

Drug Class	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral
Mechanism of Action	DNA Polymerase Inhibitors

Medical Subject Heading (MeSH) Categories for ganciclovir

Antiviral Agents

Anatomical Therapeutic Chemical (ATC) Classes for ganciclovir

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AD	Antivirals
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ganciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	GANCICLOVIR SODIUM	ganciclovir sodium	INJECTABLE;INJECTION	076222-001	Jul 16, 2003	AP	RX	No	No
Pharmascience Inc	GANCICLOVIR SODIUM	ganciclovir sodium	INJECTABLE;INJECTION	207645-001	Dec 8, 2017	AP	RX	No	Yes
Bausch And Lomb	ZIRGAN	ganciclovir	GEL;OPHTHALMIC	022211-001	Sep 15, 2009		RX	Yes	Yes
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994		DISCN	Yes	No
Cheplapharm	CYTOVENE	ganciclovir sodium	INJECTABLE;INJECTION	019661-001	Jun 23, 1989		DISCN	Yes	No

Expired US Patents for ganciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997
Bausch And Lomb	VITRASERT	ganciclovir	IMPLANT;IMPLANTATION	020569-001	Mar 4, 1996

EU/EMA Drug Approvals for ganciclovir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..	Vitrasert Implant	ganciclovir	EMEA/H/C/000120The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).	Withdrawn	no	no	no	1997-03-18

Ganciclovir (Drug) Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is ganciclovir and where does it sit in the product map?

Ganciclovir is an acyclic guanosine analog used for viral infections, with its primary commercial positioning tied to cytomegalovirus (CMV) disease. The market dynamics for ganciclovir are shaped by: (1) treatment setting (hospital vs specialty outpatient), (2) competition from branded and generic antivirals, and (3) payer reimbursement patterns that track transplant and immunocompromised populations.

Commercially, ganciclovir exposure is typically split across:

• Intravenous (IV) ganciclovir for initial CMV disease treatment in higher-acuity settings.
• Oral ganciclovir where applicable (market availability varies by geography).
• Treatment pathways where IV induction transitions to oral maintenance in some CMV regimens.

Because ganciclovir is off-patent in many jurisdictions, the financial trajectory is dominated by generic entry timing, tender pricing, formulation competition, and relative clinical positioning versus alternatives (notably valganciclovir-based regimens in CMV disease prevention and treatment).

How does the competitive landscape move the price and volume?

The CMV antiviral landscape compresses pricing over time. Key dynamics that govern ganciclovir financial performance:

1) Generic pressure is the dominant pricing driver

Ganciclovir’s economics are typically determined less by innovation cycles and more by:

• Generic substitution through formularies and tendering.
• Inventory and distribution leverage from larger generic manufacturers.
• Regulatory and sourcing reliability during hospital procurement cycles.

In practice, pricing trends for older antivirals with mature supply chains tend to follow the pattern:

• Early branded period: higher list price, limited supply constraints.
• Post-generic entry: steep margin compression.
• Mature stage: price stabilization at lower levels driven by procurement scale.

2) Valganciclovir limits upside for IV/oral ganciclovir

Valganciclovir has displaced much CMV management in many markets because oral valganciclovir supports simpler outpatient workflows after induction. This shifts demand away from IV ganciclovir and constrains volume growth, especially in markets where valganciclovir is preferred for CMV maintenance or prophylaxis pathways.

3) Hospital formularies gate volume

For IV ganciclovir, adoption depends on:

• Hospital formulary decisions in transplant centers and oncology/immunology units.
• Pharmacy and therapeutics committee protocols that often standardize regimens for CMV.

Once standardized, switching costs slow volume reallocation even if pricing changes.

Which demand pockets most influence ganciclovir revenue?

Ganciclovir’s market demand tracks CMV incidence and treatment intensity in immunocompromised populations. The highest sensitivity demand pockets are:

1) Solid organ and hematopoietic transplant care pathways

CMV disease incidence rises with:

• Transplant type and donor-recipient risk profile.
• Immunosuppression intensity.
• Use of prophylaxis versus pre-emptive monitoring strategies.

Where a payer or provider network uses pre-emptive therapy and triggers treatment based on viral load, antiviral utilization can be steadier than purely prophylaxis-only models.

2) Oncology and immunology immunosuppression regimes

Certain cancer and immunomodulatory therapies drive CMV reactivation risk. This can stabilize demand even when transplant volumes fluctuate.

3) Regional payer policies on antivirals

Payer preference for cost-effective regimens and clinical pathway alignment can materially affect which antiviral is used first-line and which is reserved as second-line or backup therapy.

How do supply-chain and procurement patterns shape financial trajectory?

Ganciclovir’s financial trajectory is usually defined by working-capital and procurement realities rather than R&D milestones:

• Tender pricing cycles: Hospital and group purchasing organizations reset costs based on competitive bids.
• NDC-level supply stability: Shortages can temporarily lift pricing or reallocation across suppliers, but mature products typically resolve shortages quickly.
• Margin structure: Generic economics often compress gross margin; companies compete through scale, manufacturing efficiency, and distribution coverage.

For an off-patent antiviral, the “financial trajectory” often reads as a sequence:

• Declining net price after generic entry
• Flat-to-slight volume declines or stable volume with cyclical tender resets
• Occasional temporary rebounds during supply disruptions or procurement transitions

What is the likely revenue pattern across the lifecycle?

With ganciclovir’s mature status, the revenue pattern is generally:

• Peak during branded dominance (historically)
• Decline after meaningful generic penetration
• Stabilization at a lower net-price band due to entrenched formularies and ongoing CMV incidence

Unlike newer antivirals with patent-protected franchise dynamics, ganciclovir’s long-run financial direction is primarily governed by:

• generic market share shifts,
• tender outcomes,
• and displacement by oral valganciclovir pathways.

How does pipeline risk and label strategy affect future value?

Ganciclovir itself does not drive a typical blockbuster trajectory in the same way as late-stage pipeline assets because:

• The asset is not anchored to a dominant patent-driven exclusivity window in most major markets.
• Business value tends to come from manufacturing footprint, formulation differentiation (where permitted), and distribution contracts rather than new clinical claims.

Future value inflection would typically be tied to:

• new formulation approvals that improve administration convenience or reduce cost (where regulators allow),
• or changes in CMV standard-of-care that shift utilization back toward ganciclovir.

Absent a major guideline reversal, structural pressure from competitors remains the dominant determinant.

---

Financial trajectory: what the market structure implies for revenue and earnings

Below is the practical earnings logic that governs ganciclovir branded-to-generic transitions and ongoing generic competition. It is framed for business and investment use: how revenue quality changes as pricing compresses.

Financial lever	Typical direction in mature ganciclovir markets	Business impact
Net price	Downward after generic entry; later stabilizes	Margin compression, dependence on volume and scale
Volume	Flat to modestly declining as regimens shift to alternatives	Revenue becomes procurement- and guideline-sensitive
Gross margin	Low and pressured; margin variance by supplier cost position	Earnings volatility tied to manufacturing efficiency
Market share	Redistributed via tenders and contracting	Winning share often comes from bid competitiveness and reliability
Cash conversion	Working-capital tied to inventory and supplier lead times	Supply planning quality affects net cash more than brand strategy

---

Key market scenarios that change the financial curve

Scenario A: Continued displacement toward oral regimens

If CMV treatment pathways continue to prefer valganciclovir for outpatient maintenance, ganciclovir volumes stay capped. The revenue curve flattens but does not rebound.

Scenario B: Tender consolidation among fewer large generic suppliers

If fewer suppliers secure contracts, pricing can stabilize at slightly higher levels due to reduced competitive bidding intensity. Earnings can improve for winners with lower unit costs, but industry-wide prices remain structurally lower than pre-generic.

Scenario C: Local supply constraints

Supply disruptions at the NDC or batch level can temporarily tighten availability and lift realized prices. The upside tends to be short-cycle unless supply reform or regulatory actions change the competitive set.

---

What metrics matter most for investors and commercial planners?

For ganciclovir, the most decision-relevant metrics are:

1. Tender-weighted net pricing (not list price)
2. Share of CMV regimen selection by indication setting (transplant vs oncology)
3. Channel mix (hospital pharmacy procurement vs specialty distribution)
4. Inventory availability metrics (OTIF, lead times)
5. Competitive set composition (number of approved competitors per NDC/strength/form)

These metrics determine whether a participant benefits from market share stability or suffers from repeated contract losses.

---

Key Takeaways

• Ganciclovir’s market dynamics are dominated by generic pricing, hospital procurement, and displacement from valganciclovir-based pathways, not by new exclusivity-driven expansion.
• Financial trajectory typically follows a post-generic decline into low net-price stabilization, with modest volume movement driven by transplant and immunocompromised CMV incidence.
• Earnings are shaped by tender outcomes, manufacturing unit-cost competitiveness, and supply reliability, making cash flow and gross margin variance more important than product innovation milestones.
• Upside scenarios are usually temporary (supply constraints) or supplier-specific (procurement wins), rather than broad market growth.

---

FAQs

1) Is ganciclovir a growth franchise in the current CMV market?

No. Market structure favors cost-led procurement and regimen preference toward alternatives, so growth is typically limited to share gains from contract wins rather than category expansion.

2) What drives ganciclovir revenue most: incidence or pricing?

Pricing usually dominates in mature markets due to generic substitution and tender compression, while incidence drives baseline utilization.

3) Which setting has the strongest impact on ganciclovir demand?

Hospital transplant and immunocompromised care pathways, where IV induction and treatment protocols govern utilization.

4) What is the main commercial risk to ganciclovir?

Continued displacement toward valganciclovir-based regimens and further generic penetration that increases competitive bidding pressure.

5) What matters for profitability more than top-line growth?

Manufacturing cost position, contract win rate, and supply reliability that reduce margin leakage during procurement cycles.

---

References

[1] Lexicomp Online. Ganciclovir: Drug Information. Wolters Kluwer.
[2] FDA. Drug Approval Package: Cytovene (ganciclovir) (labeling and review materials). U.S. Food and Drug Administration.
[3] EMA. Summary of Product Characteristics: ganciclovir-containing medicinal products (where applicable by reference product). European Medicines Agency.